Market Turmoil: CSL's Deepening Crisis and ASX Leadership Shake-Up

Multiple Australian corporations have reported substantial operational and financial difficulties during the current earnings season, with the Australian Securities Exchange (ASX) also undergoing a leadership transition amid regulatory scrutiny.

CSL Financial Performance and Outlook

Share Price Collapse

CSL shares fell as much as 20% to A$93.63 on Monday, May 11, 2026, reaching a decade low.

The share price has declined from approximately A$270 to about A$150, representing an eight-year low. The company's market capitalization has fallen by approximately A$105 billion from its peak over the past two years. Investors have lost a collective A$88 billion since August 2025.

Devastating Financial Results

Acting CEO Gordon Naylor announced a US$5 billion (A$6.9 billion) write-down in asset value and revised downward revenue and earnings forecasts for the fiscal year ending June 30, 2026. Revenue is now expected to be approximately US$15.2 billion, below analyst estimates of US$15.8 billion. Net profit of US$3.1 billion is US$200 million less than market forecasts.

For the half-year ending December 2025, CSL reported US$1.1 billion (A$1.55 billion) in one-off impairments and missed market estimates. This represents an 81% decline in half-year earnings. Full-year guidance was revised downward, with revenue and underlying profit now expected to decline, contrary to previous forecasts of 2–3% revenue growth and 4–7% earnings growth. CSL issued its third downgrade in less than a year.

Key Factors Behind the Downgrade

The Vifor Acquisition Disaster

The US$11.7 billion acquisition of Vifor in 2022 has encountered significant challenges. The company applied a US$5 billion writedown to the Vifor business due to generic competition for its iron-deficiency products. Uncertainty remains regarding the scale of future write-offs. The company has acknowledged the timing of the acquisition was not optimal.

Intensifying Competition

Naylor's 90-day review revealed that competitors have strengthened supply chains and developed products that challenged CSL's innovative lead, with CSL being slow to respond. The plasma business lost market share in the US to rivals including Grifols. Generic competition in the US market for iron-based products adds further uncertainty.

Product Development Failures

A phase 3 trial failure for a heart attack drug in 2024 prompted a research restructuring and loss of 3,000 jobs.

Operational Inefficiencies

CSL's growing asset base has been "less productive than anticipated" and the company "overbuilt organizational capacity." The company took a US$300 million charge to normalize inventory in the US plasma market and a US$200 million hit from Chinese albumin business due to hospital budget restrictions.

Vaccines Business (Seqirus) in Decline

The vaccines business has experienced declining vaccination rates in the US. Chairman Brian McNamee noted that vaccination rates in the US dropped another 14–15% despite severe flu seasons. Plans to spin off Seqirus have been shelved, though a spin-off remains planned when the US market recovers.

Management Turmoil

CEO Paul McKenzie resigned abruptly in February 2026, before the half-year results announcement. Chairman Brian McNamee stated that McKenzie no longer had the skills desired for the future. Gordon Naylor, a former CSL executive, was appointed interim CEO. He later conducted a review and announced the downgrade. The board is conducting a search for a permanent CEO.

Cost-Saving Measures

Cost savings of up to US$550 million are underway since last year.

Response from Naylor

Naylor stated that the growth ambitions declared for the current half have not been realized. He noted that the fundamental industry characteristics remain structurally stable and growing, but a quick turnaround is not expected.

Analyst Observations

• Morningstar analyst Shane Ponraj described the downgrade as "a collision with reality" and noted CSL is "clearing the decks."
• Bell Potter analyst Thomas Wakim stated that a discount is warranted given the declining earnings outlook, lack of stable management, and credibility hits.
• Macquarie Equities noted that CSL's price-to-earnings multiple fell from over 44x during COVID to about 10x.
• A fund manager (anonymous) questioned the board's knowledge of the business.
• AllianceBernstein portfolio manager Anja Samardzic attributed problems to complacency and said CSL needs to "rebuild credibility with the market."

Australian Securities Exchange (ASX) Leadership Transition

CEO Departure

Helen Lofthouse, CEO of the Australian Securities Exchange (ASX), is scheduled to depart in May 2026 after four years in the role, two days prior to the scheduled release of ASX results.

The CHESS Replacement Project: A Decade of Failure

The ASX has faced challenges over approximately a decade, particularly regarding the replacement of its CHESS trading system. In 2015, the ASX began searching for a CHESS replacement. In 2017, it announced plans to use blockchain technology on an industrial scale. The project faced an ambitious three-year timeline with insufficient planning for interaction with supporting service providers and disputes among information providers. Concerns were raised by share registries and custodians regarding potential business loss.

The project experienced five delays before being canceled in late 2022, resulting in a A$250 million write-off for the ASX. Investment houses had already incurred significant costs in system integration efforts. Dominic Stevens, Lofthouse's predecessor and the project's commissioner, resigned earlier in 2022.

Regulatory Scrutiny Intensifies

The Australian Securities and Investments Commission (ASIC) and the Reserve Bank of Australia (RBA) oversee the ASX. Both regulators expressed strong dissatisfaction with the project's failure.

An independent review by Accenture identified significant gaps in ASX's program delivery capabilities and technology design. ASIC Chair Joe Longo stated the findings were "altogether unsatisfactory."

In June 2023, ASIC launched a broad inquiry into the ASX's capacity to maintain stable, secure, and resilient critical market infrastructure, citing "repeated and serious failures."

ASIC recently issued a report questioning the ASX's ability to operate the national stock exchange, accusing it of prioritizing short-term profits over vital infrastructure management. ASIC highlighted significant deficiencies in the ASX's culture, governance, and technology, and mandated an additional A$150 million in liquid assets to improve its financial position.

Continued System Instability

After Lofthouse assumed leadership, the 25-year-old CHESS system, serving as a temporary solution, experienced repeated outages and shutdowns. A notable incident occurred before Christmas 2023, hindering trade settlements and prompting ASIC Chair Longo to express significant concern and indicate potential further regulatory action.

The TPG Telecom Error

A subsequent error involved the ASX confusing TPG Telecom with an unrelated foreign private equity group, leading to TPG Telecom losing A$400 million in market value. The ASX's inability to promptly correct the mistake exacerbated the situation.

Monopoly Under Threat

ASIC announced it was considering approving a rival exchange, CBOE Australia, to operate alongside the ASX.

Recent Developments

The April 2026 launch of the first stage of a new automated technology for settling share trades occurred before Lofthouse's departure. An incident was reported where CSL announced its CEO's departure after trading hours, and extended trading times led to immediate share price impacts. Confusion arose regarding the percentage decline, with discrepancies appearing on the ASX website and third-party systems.

Lofthouse acknowledged the errors. Her successor, yet to be named, will face the task of restoring confidence in the institution.

Commonwealth Bank Performance

In contrast, Commonwealth Bank (CBA) delivered a robust financial result. Its chief executive, Matt Comyn, has overseen a strong performance amid intense banking sector competition.

Background on CSL

CSL is a global biotech company specializing in plasma-derived therapies, vaccines, and iron-deficiency treatments. The company has faced headwinds from US pricing pressures, COVID-19 vaccine fatigue, and competition in its core plasma business. The board is chaired by former CEO Brian McNamee. These companies are significant components of many Australian superannuation portfolios.